Bigul

Ortin Laboratories Ltd - 539287 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyOrtin Laboratories Ltd 2CIN NO.L24110TG1986PLC006885 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nitesh Kumar Sharma Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: S Srinivas Kumar Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
29-04-2023
Bigul

Ortin Laboratories Ltd - 539287 - Compliance Certificate U/R 40(9)

Compliance Certificate u/r 40(9)
29-04-2023
Bigul

Ortin Laboratories Ltd - 539287 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg 74(5) for the quarter and year ended 31.03.2023
21-04-2023
Bigul

Ortin Laboratories Ltd - 539287 - Compliance Certificate U/R 7(3) For The Quarter And Year Ended 31.03.2023

Compliance Certificate u/r 7(3) for the quarter and year ended 31.03.2023
21-04-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Ravi Sankar
29-03-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srinivasa Kumar Sanka
29-03-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Venkata Subbamma
29-03-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Hema Kumari
29-03-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanka Sarath Kumar
29-03-2023
Bigul

Ortin Laboratories Ltd - 539287 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Murali Krishna Murthy Sanka
29-03-2023
Next Page
Close

Let's Open Free Demat Account